Clinical Trial Search

Primary: Peak FEV1 Within 3 Hours Post-dose Response — 0.053; 0.289; 0.250; 0.266 Litre — p=<0.0001

Primary: Peak FEV1 Within 3 Hours Post-dose Response — 0.075; 0.287; 0.244; 0.252 Litre — p=<0.0001

Primary: Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period — 32; 6; 103; 10 Participants

Primary: Overall Survival: Time From Randomization to Date of Death — 21.2; 21.5 Months — p=0.9009

Primary: Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation — 0; 0; 0; 5 Participants

Primary: Change From Baseline Trough in 24-Hour Weighted Mean FEV1 on Treatment Day 84 — 0.114; 0.142 Liters — p=0.267

Primary: The Primary Outcome Measure Was a Patient Global Assessment of Change (PGIC) Scale. — 3.3 units on a scale

Primary: The Success Rate — 95.2 percentage of participants

Primary: Change From Baseline in Hemoglobin A1C (A1C) at Week 24 — -1.67; -1.83; -1.29; -1.56 Percent of glycosylated hemoglobin — p=0.087

Primary: Change in Attention Deficit Hyperactivity Disorder Rating Scale - IV (ADHD-RS-IV) Total Score From Baseline to 8-week Follow-up Visit — 39.9; 13.8 units on a scale…

Primary: Change in Synovitis Measured by Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Image Scoring System (RAMRIS)…

Primary: Double-blind Change From Baseline in Ashworth Score Evaluating Spasticity — -0.28; -0.16 units on a scale

Primary: Progression Free Survival (PFS): First-Line Participants — 10.1; 6.5 months

Primary: Body Weight (Amount of Change) — -0.45; -1.54 Kg — p=<0.0001

Primary: Percentage of Participants With Anti HBs Seroprotection After the 3 Dose Primary Vaccination Series With Either DTaP-IPV-Hep B-PRP~T or PENTAXIM™ + ENGERIX B® Vaccines…